Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Patrick Loehrer, MD
Primary Investigator
Overview
The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Pancreatic Ductal Adenocarcinoma, pancreatic cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Untreated locally advanced PDAC
Histologically or cytologically confirmed PDAC
Adequate organ function
Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of study treatment.